ADMA Biologics, Inc (NASDAQ:ADMA) Accelerates Buybacks While Technicals Signal Near-Term Rebound

Balance-sheet strength and an accelerated share-repurchase program sit alongside oversold technicals, creating a setup that favors a measured recovery attempt in the near term. Operational margin expansion and strong cash generation underpin the valuation case.

Recent News

On March 2, 2026 ADMA announced a $125 million accelerated share-repurchase with J.P. Morgan as part of a planned $200 million 2026 repurchase initiative. In April–May 2026 multiple law firms publicized investigations and potential securities class-action activity related to the company, and an analyst group adjusted coverage and price targets in the wake of recent corporate disclosures.

Technical Analysis

Directional indicators (ADX / DI+ / DI-): ADX at 31.17 indicates a strong directional regime; DI+ shows a dip-and-reversal while DI− shows a peak-and-reversal, a configuration that points to bullish directional reconfiguration despite DI− remaining numerically above DI+.

MACD: MACD sits at −0.73 with a dip-and-reversal pattern, indicating bullish momentum emerging from a negative base; no confirmed MACD crossover above the signal line exists at the reported values.

MRO (Momentum/Regression Oscillator): MRO reads −29.62, which places the price below the model target and implies potential upward pressure as the market closes the gap toward target levels.

RSI: RSI at 37.21 with a dip-and-reversal indicates prior oversold conditions beginning to reverse, supporting near-term strength if momentum holds.

Price versus moving averages and cloud: Closing price $8.56 tracks below the 20‑day average ($8.92), 50‑day average ($10.69) and 200‑day average ($15.24); the 12‑day EMA trend remains decreasing. Ichimoku Tenkan/Kijun (9.07 / 9.46) lie above price while Senkou span A/B sit near $11.55 / $12.61, indicating the price remains under the larger cloud resistance despite short-term reversal signals.

Bollinger bands & volatility: Price sits between the 1x Bollinger bands ($7.89–$9.95) and below the super-trend upper band ($9.68), consistent with a mean‑reversion opportunity inside a still-elevated volatility regime (42‑day beta ~1.09).

 


Fundamental Analysis

Profitability & margins: EBIT equals $59,227,000 and EBIT margin stands at 51.73%, a level substantially above the industry peer mean (−1.10%) and industry peer median (0.23%), with EBIT margin improving 13.87% QoQ and 67.64% YoY. Operating margin of 43.93% and gross margin of 70.53% confirm significant margin expansion versus recent periods.

Revenue and earnings: Total revenue reported $114,493,000. Reported EPS came in at $0.17 versus an estimate of $0.20, a −$0.03 miss (−15.00% surprise). Reported revenue growth figures include a QoQ change of −581.71% and a YoY change of 658.54% as provided; earnings growth YoY recorded 6.06% while QoQ earnings growth contracted per the supplied values.

Cash flow and liquidity: Cash and short‑term investments total $138,153,000 with operating cash flow $52,105,000 and free cash flow $55,653,000; cash conversion ratio 26.16% and cash ratio 187.86% indicate strong near‑term liquidity. Net debt sits at $58,712,000 and interest coverage around 28.20x supports manageable debt service.

Balance‑sheet health & working capital: Current ratio 6.95 and quick ratio 3.93 show very strong short‑term coverage; net working capital $437,632,000 and inventory at $222,098,000 drive a long cash conversion cycle reported at 466.64 days.

Valuation context: WMDST values the stock as under‑valued. Market multiples show a P/E of 74.24 and EV/Revenue and EV multiples consistent with a premium; P/B at 7.51 sits near the industry peer mean (7.64). Free cash flow yield registers 1.90% on reported free cash flow, while enterprise multiple reads ~49.09x. Margin expansion, strong operating cash conversion and the active share‑repurchase program support WMDST’s under‑valued determination when measured against the company’s cash generation profile.

MOST-RECENT QUARTERLY REPORT
REPORT PERIOD ENDING: 2026-03-31
REPORT DATE: 2026-05-06
NEXT REPORT DATE: 2026-08-05
CASH FLOW  Begin Period Cash Flow 87.6 M
 Operating Cash Flow 52.1 M
 Capital Expenditures -2.60 M
 Change In Working Capital 9.2 M
 Dividends Paid
 Cash Flow Delta 50.5 M
 End Period Cash Flow 138.2 M
 
INCOME STATEMENT REVENUE
 Total Revenue 114.5 M
 Forward Revenue 38.7 M
COSTS
 Cost Of Revenue 33.7 M
 Depreciation 1.8 M
 Depreciation and Amortization 1.8 M
 Research and Development 2.6 M
 Total Operating Expenses 64.2 M
PROFITABILITY
 Gross Profit 80.8 M
 EBITDA 61.1 M
 EBIT 59.2 M
 Operating Income 50.3 M
 Interest Income 1.1 M
 Interest Expense 2.1 M
 Net Interest Income -1.01 M
 Income Before Tax 57.1 M
 Tax Provision 11.8 M
 Tax Rate 20.654 %
 Net Income 45.3 M
 Net Income From Continuing Operations 45.3 M
EARNINGS
 EPS Estimate 0.20
 EPS Actual 0.17
 EPS Difference -0.03
 EPS Surprise -15.0 %
 Forward EPS 0.26
 
BALANCE SHEET ASSETS
 Total Assets 665.2 M
 Intangible Assets 4.2 M
 Net Tangible Assets 386.2 M
 Total Current Assets 511.2 M
 Cash and Short-Term Investments 138.2 M
 Cash 138.2 M
 Net Receivables 135.9 M
 Inventory 222.1 M
 Long-Term Investments 8.5 M
LIABILITIES
 Accounts Payable 20.5 M
 Short-Term Debt 3.3 M
 Total Current Liabilities 73.5 M
 Net Debt 58.7 M
 Total Debt 204.4 M
 Total Liabilities 274.9 M
EQUITY
 Total Equity 390.3 M
 Retained Earnings -116.33 M
VALUATION & PER-SHARE METRICS EQUITY & PER-SHARE METRICS
 Book Value Per-Share 1.68
 Shares Outstanding 232.289 M
 Revenue Per-Share 0.49
VALUATION
 Market Capitalization 2.9 B
 Enterprise Value 3.0 B
 Enterprise Multiple 49.095
Enterprise Multiple QoQ -20.986 %
Enterprise Multiple YoY -61.434 %
Enterprise Multiple IPRWA high: 75.51
ADMA: 49.095
median: 29.168
mean: 8.753
low: -128.217
 EV/R 26.185
CAPITAL STRUCTURE
 Asset To Equity 1.704
 Asset To Liability 2.42
 Debt To Capital 0.344
 Debt To Assets 0.307
Debt To Assets QoQ 140.127 %
Debt To Assets YoY 91.303 %
Debt To Assets IPRWA high: 1.112
ADMA: 0.307
mean: 0.258
median: 0.168
low: 0.0
 Debt To Equity 0.524
Debt To Equity QoQ 212.906 %
Debt To Equity YoY 138.437 %
Debt To Equity IPRWA high: 1.864
ADMA: 0.524
mean: 0.307
median: 0.103
low: -1.094
PRICE-BASED VALUATION
 Price To Book (P/B) 7.511
Price To Book QoQ -11.762 %
Price To Book YoY -40.951 %
Price To Book IPRWA high: 20.609
mean: 7.638
ADMA: 7.511
median: 5.613
low: -11.267
 Price To Earnings (P/E) 74.242
Price To Earnings QoQ -4.376 %
Price To Earnings YoY -58.989 %
Price To Earnings IPRWA ADMA: 74.242
high: 73.877
mean: -1.798
median: -14.354
low: -125.804
 PE/G Ratio -3.267
 Price To Sales (P/S) 25.606
Price To Sales QoQ -12.296 %
Price To Sales YoY -38.111 %
Price To Sales IPRWA high: 864.732
mean: 65.239
median: 29.192
ADMA: 25.606
low: 0.85
FORWARD MULTIPLES
Forward P/E 58.004
Forward PE/G -2.552
Forward P/S 75.66
EFFICIENCY OPERATIONAL
 Operating Leverage 0.356
ASSET & SALES
 Asset Turnover Ratio 0.178
Asset Turnover Ratio QoQ -23.882 %
Asset Turnover Ratio YoY -22.713 %
Asset Turnover Ratio IPRWA high: 0.365
ADMA: 0.178
mean: 0.104
median: 0.094
low: 0.0
 Receivables Turnover 0.778
Receivables Turnover Ratio QoQ -17.222 %
Receivables Turnover Ratio YoY -49.367 %
Receivables Turnover Ratio IPRWA high: 4.628
mean: 1.264
median: 1.226
ADMA: 0.778
low: 0.013
 Inventory Turnover 0.157
Inventory Turnover Ratio QoQ -36.957 %
Inventory Turnover Ratio YoY -49.799 %
Inventory Turnover Ratio IPRWA high: 2.566
mean: 0.503
median: 0.358
ADMA: 0.157
low: 0.003
 Days Sales Outstanding (DSO) 117.274
CASH CYCLE
 Cash Conversion Cycle Days (CCC) 466.637
Cash Conversion Cycle Days QoQ 24.528 %
Cash Conversion Cycle Days YoY 48.997 %
Cash Conversion Cycle Days IPRWA high: 930.567
ADMA: 466.637
mean: 230.275
median: 208.031
low: -1062.776
CAPITAL DEPLOYMENT
 Cash Conversion Ratio 0.262
 CapEx To Revenue -0.023
 CapEx To Depreciation -1.455
 
CAPITAL, LIQUIDITY & COVERAGE CAPITAL STRUCTURE
 Total Capital 583.9 M
 Net Invested Capital 587.2 M
 Invested Capital 587.2 M
 Net Tangible Assets 386.2 M
 Net Working Capital 437.6 M
LIQUIDITY
 Cash Ratio 1.879
 Current Ratio 6.951
Current Ratio QoQ 3.614 %
Current Ratio YoY 5.697 %
Current Ratio IPRWA high: 34.334
ADMA: 6.951
mean: 5.622
median: 3.485
low: 0.05
 Quick Ratio 3.931
Quick Ratio QoQ 5.116 %
Quick Ratio YoY 17.071 %
Quick Ratio IPRWA high: 13.886
ADMA: 3.931
mean: 2.815
median: 2.568
low: 0.164
COVERAGE & LEVERAGE
 Debt To EBITDA 3.347
 Cost Of Debt 1.172 %
 Interest Coverage Ratio 28.203
Interest Coverage Ratio QoQ -27.463 %
Interest Coverage Ratio YoY 57.238 %
Interest Coverage Ratio IPRWA high: 604.866
ADMA: 28.203
mean: 17.353
median: 4.172
low: -1643.72
 Operating Cash Flow Ratio 0.709
TIMING / LIQUIDITY
 Days Payables Outstanding (DPO) 39.005
DIVIDENDS
 Dividend Coverage Ratio
 Dividend Payout Ratio
 Dividend Rate
 Dividend Yield
PERFORMANCE GROWTH
 Asset Growth Rate 6.559 %
 Revenue Growth -17.727 %
Revenue Growth QoQ -581.712 %
Revenue Growth YoY 658.537 %
Revenue Growth IPRWA high: 242.212 %
median: -7.584 %
mean: -10.858 %
ADMA: -17.727 %
low: -242.388 %
 Earnings Growth -22.727 %
Earnings Growth QoQ -148.7 %
Earnings Growth YoY 6.057 %
Earnings Growth IPRWA high: 200.0 %
median: -5.263 %
mean: -8.812 %
ADMA: -22.727 %
low: -247.826 %
MARGINS
 Gross Margin 70.528 %
Gross Margin QoQ 10.507 %
Gross Margin YoY 32.524 %
Gross Margin IPRWA high: 100.0 %
median: 81.912 %
mean: 78.254 %
ADMA: 70.528 %
low: -58.949 %
 EBIT Margin 51.73 %
EBIT Margin QoQ 13.87 %
EBIT Margin YoY 67.644 %
EBIT Margin IPRWA high: 2524.194 %
ADMA: 51.73 %
median: 23.412 %
mean: -110.019 %
low: -5917.523 %
 Return On Sales (ROS) 43.928 %
Return On Sales QoQ -2.581 %
Return On Sales YoY 42.36 %
Return On Sales IPRWA high: 100.302 %
ADMA: 43.928 %
median: 20.658 %
mean: -109.737 %
low: -5917.523 %
CASH FLOW
 Free Cash Flow (FCF) 55.7 M
 Free Cash Flow Yield 1.898 %
Free Cash Flow Yield QoQ 124.35 %
Free Cash Flow Yield YoY -469.261 %
Free Cash Flow Yield IPRWA high: 11.709 %
ADMA: 1.898 %
median: 0.11 %
mean: -0.476 %
low: -38.469 %
 Free Cash Growth 61.956 %
Free Cash Growth QoQ -101.879 %
Free Cash Growth YoY -140.923 %
Free Cash Growth IPRWA high: 253.163 %
ADMA: 61.956 %
median: 22.969 %
mean: 11.103 %
low: -249.577 %
 Free Cash To Net Income 1.228
 Cash Flow Margin 45.509 %
 Cash Flow To Earnings 1.15
VALUE & RETURNS
 Economic Value Added 0.04
 Return On Assets (ROA) 7.031 %
Return On Assets QoQ -15.074 %
Return On Assets YoY 30.566 %
Return On Assets IPRWA high: 24.58 %
ADMA: 7.031 %
median: 1.213 %
mean: -2.981 %
low: -54.76 %
 Return On Capital Employed (ROCE) 10.011 %
 Return On Equity (ROE) 0.116
Return On Equity QoQ 12.257 %
Return On Equity YoY 61.18 %
Return On Equity IPRWA high: 0.784
ADMA: 0.116
median: 0.023
mean: 0.0
low: -1.109
 DuPont ROE 10.449 %
 Return On Invested Capital (ROIC) 8.003 %
Return On Invested Capital QoQ -13.237 %
Return On Invested Capital YoY 25.262 %
Return On Invested Capital IPRWA high: 41.877 %
ADMA: 8.003 %
median: 3.585 %
mean: 1.553 %
low: -51.333 %

Six-Week Outlook

Expect elevated volatility as buyback activity and legal developments continue to trade through headlines. Technicals point to a near‑term recovery attempt: oversold RSI reversing, MRO below target, and MACD showing emerging upward momentum. Price remains below key moving averages and Ichimoku cloud resistance, so any rally will likely encounter layered supply near the $9.50–$12 area on the path back toward the 50‑day average. Liquidity and margin strength reduce downside risk from an operational perspective, but headline flow (repurchase cadence and legal developments) likely dictates short‑term intraday swings.

About ADMA Biologics, Inc.

ADMA Biologics, Inc. (NASDAQ:ADMA) is a cutting-edge biopharmaceutical company dedicated to the innovation, production, and marketing of specialized plasma-derived biologics. With a focus on addressing immune deficiencies and infectious diseases, ADMA Biologics plays a crucial role in enhancing patient care both domestically and internationally. The company’s flagship products include BIVIGAM and ASCENIV, both intravenous immune globulin (IVIG) therapies specifically formulated to treat primary humoral immunodeficiency (PI). Additionally, ADMA offers Nabi-HB, a vital treatment for individuals with acute exposure to Hepatitis B. ADMA Biologics is not only committed to its current product line but is also actively developing a robust pipeline of new plasma-derived therapies aimed at preventing and treating infections such as those caused by S. pneumonia. To ensure a consistent supply of high-quality plasma, the company operates its own plasma collection centers, which are integral to its manufacturing process. Established in 2004 and headquartered in Ramsey, New Jersey, ADMA Biologics distributes its products through a comprehensive network of independent distributors, drug wholesalers, specialty pharmacies, and alternate site providers. The company continues to make significant contributions to the biopharmaceutical industry, advancing healthcare solutions for those in need.



© 2026 WMDST — The World’s Most Dangerous Swing Trader. All rights reserved.